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Efforts to achieve an effective cure against 
malignant diseases are commonly thwarted by 
the rapid emergence of therapy-resistant can-
cer cells that serve as the basis for resurgence 
of the tumor despite initial shrinkage. High 
hopes were placed on the development of an-
tiangiogenic drugs, as it was thought that this 
class of agents would be inherently impervi-
ous to mechanisms of acquired resistance by 
means of targeting the nonmalignant and ge-
netically stable tumor endothelial cells (Kerbel, 
1991, 1997). However, the initial clinical ex-
perience with drugs selectively targeting the 
tumor neovasculature, such as bevacizumab, 
sunitinib, and sorafenib, has been sobering. Major 
clinical responses to these drugs, with target-
ing of the prototypical proangiogenic vascular 
endothelial growth factor (VEGF) as a com-
mon denominator, are rare, and the median pro-
longation of progression-free survival is typically 
2–6 mo with minimal effect on overall survival 
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Therapy-induced resistance remains a significant hurdle to achieve long-lasting responses 
and cures in cancer patients. We investigated the long-term consequences of genetically 
impaired angiogenesis by engineering multiple tumor models deprived of endoglin,  
a co-receptor for TGF- in endothelial cells actively engaged in angiogenesis. Tumors 
from endoglin-deficient mice adapted to the weakened angiogenic response, and  
refractoriness to diminished endoglin signaling was accompanied by increased metastatic 
capability. Mechanistic studies in multiple mouse models of cancer revealed that  
deficiency for endoglin resulted in a tumor vasculature that displayed hallmarks of  
endothelial-to-mesenchymal transition, a process of previously unknown significance  
in cancer biology, but shown by us to be associated with a reduced capacity of the  
vasculature to avert tumor cell intra- and extravasation. Nevertheless, tumors deprived 
of endoglin exhibited a delayed onset of resistance to anti-VEGF (vascular endothelial 
growth factor) agents, illustrating the therapeutic utility of combinatorial targeting of 
multiple angiogenic pathways for the treatment of cancer.
© 2013 Anderberg et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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endoglin appears as a valid therapeutic target for efforts to 
suppress tumor angiogenesis, but it is not known whether 
the long-term efficacy of such targeting would be limited by 
induction of adaptive mechanisms.
Here, we have delineated a novel mode of metastatic dis-
semination associated with tumors refractory to attenuated 
expression of endoglin. Deficiency for even a single copy of 
endoglin was characterized by an increased seeding of metas-
tases caused by a weakened endothelial cell barrier to tumor 
cell intra- and extravasation. Strikingly, endoglin-deficient endo-
thelial cells adapted a more mesenchymal phenotype conse-
quential to enhanced signaling through the TGF- type I 
receptor ALK5; increased endothelial-to-mesenchymal tran-
sition (EndMT) in the tumor vasculature thus constitutes a 
novel mechanism for metastatic dissemination.
RESULTS
Endoglin deficiency results in angiogenic adaptation  
and increased metastatic spread
To determine the impact of genetic ablation of endoglin in 
the tumor vasculature, we first devised a set of studies using 
the prototypical RIP1-Tag2 mouse model of multistep de-
velopment of pancreatic neuroendocrine tumors (PNETs; 
Hanahan, 1985). Tumors of RIP1-Tag2 mice arise from the 
-cells of the pancreatic islets of Langerhans consequential to 
expression of the SV40 large T-antigen under control of the 
insulin promoter. After hyperplasia, the -cell islets go through 
sequential premalignant and angiogenic stages of tumorigen-
esis (prevalent at 8–10 wk of age) before developing into 
locally invasive and metastatic carcinomas (at 12 wk of age). 
Previous work has underscored the clinical applicability of 
the RIP1-Tag2 model by accurately predicting the efficacy of 
recently approved targeted agents against VEGF and mTOR 
signaling for PNET (Pàez-Ribes et al., 2009; Chiu et al., 2010; 
Raymond et al., 2011; Yao et al., 2011).
First, we characterized the mRNA expression of endo-
glin in normal, hyperplastic, angiogenic, and tumorous pan-
creatic islets. Endoglin exhibited a peak of expression during 
the onset of angiogenesis, implying a functional role in the 
transition from hyperplastic to angiogenic lesions (Fig. 1 a). 
The expression of endoglin, as assessed by immunostaining, 
was confined to endothelial cells in the actively proliferating 
neovasculature of malignant lesions and not evident in peri-
cytes or tumor cells (Fig. 1, b and c). Next, we made use of 
mice deficient for one copy of the endoglin gene (Eng+/) to 
analyze the impact of loss of endoglin in the context of PNET 
development. In agreement with the expression profile of 
endoglin, RIP1-Tag2;Eng+/ mice presented with fewer an-
giogenic islets at 9 wk of age, as identified under a stereologi-
cal microscope (RIP1-Tag2;Eng+/ mice [n = 6], 8 ± 1.3 vs. 
RIP1-Tag2;Eng+/+ mice [n = 7], 14.5 ± 2.9; P < 0.0001). 
The number of angiogenic islets of 12-wk-old RIP1-
Tag2;Eng+/ mice was similarly reduced by 46% compared 
with RIP1-Tag2;Eng+/+ littermates (Fig. 2 a). Isolation of 
angiogenic islets by gradient centrifugation confirmed that 
after long-term follow up (Hurwitz et al., 2004; Escudier et al., 
2007; Motzer et al., 2007). Mechanistic insight into evasive or 
intrinsic resistance to antiangiogenic therapy comes from re-
cent preclinical trials (Bergers and Hanahan, 2008; Ebos et al., 
2009b). Specifically, pharmacological inhibition of VEGF 
signaling in mouse models of cancer results in up-regulation 
of compensatory angiogenic pathways (Casanovas et al., 2005) 
and enhanced protective coverage of pericytes (Pietras and 
Hanahan, 2005). In parallel, tumors escalate the seeding of 
metastases as a result of hypoxia-induced increased local inva-
siveness (Ebos et al., 2009a; Pàez-Ribes et al., 2009). In yet 
other studies, contradictory results were presented demon-
strating no association between anti-VEGF therapy and met-
astatic behavior (Chung et al., 2012; Singh et al., 2012; Welti 
et al., 2012). Clearly, in depth mechanistic studies are war-
ranted to resolve the apparent controversies.
Members of the TGF- family act pleiotropically on 
most, if not all, cell types in the body by engaging a hetero-
tetrameric complex of type I and type II receptors (ten Dijke 
and Arthur, 2007; Massagué, 2008). Genetic targeting studies 
in mice provide ample evidence for a role of signaling by 
TGF- ligands, receptors, and downstream mediators during 
developmental angiogenesis, although the precise mechanism 
remains unclear (David et al., 2009; Cunha and Pietras, 2011; 
van Meeteren et al., 2011). Moreover, pharmacological block-
ing of signaling by the endothelial cell–restricted type I re-
ceptor activin receptor-like kinase 1 (ALK1) inhibits tumor 
growth by impairing pathological angiogenesis (Cunha et al., 
2010; Mitchell et al., 2010; Hu-Lowe et al., 2011). Signaling 
by ALK1 is complemented by the TGF- co-receptor endo-
glin (ten Dijke et al., 2008; Pérez-Gómez et al., 2010; Nassiri 
et al., 2011). Endoglin (also known as CD105) is selectively 
expressed by endothelial cells actively engaged in vasculo-
genesis, angiogenesis, and inflammation and acts to promote 
endothelial cell proliferation, migration, and tube formation 
(Jonker and Arthur, 2002; Torsney et al., 2003; Lebrin et al., 
2004; Jerkic et al., 2006). Germline mutations in the gene 
encoding endoglin are causative of the vascular syndrome 
hereditary hemorrhagic telangiectasia (HHT), character-
ized by arteriovenous malformations and frequent bleed-
ings (Shovlin, 2010), a condition partially phenocopied by 
mice lacking a single copy of Eng (Bourdeau et al., 1999; 
Li et al., 1999; Arthur et al., 2000; Torsney et al., 2003) and 
more recently in mice with endothelial-specific endoglin 
depletion (Mahmoud et al., 2010). In tumors, endoglin is 
selectively up-regulated on endothelial cells (Westphal et al., 
1993; Burrows et al., 1995; Miller et al., 1999; Bernabeu 
et al., 2009), and in many different tumor types, including 
breast, colon, and lung carcinoma, abundant expression of 
endoglin is a predictor of poor survival (Kumar et al., 1999; 
Takahashi et al., 2001b; Wikström et al., 2002; Charpin et al., 
2004; Dales et al., 2004; Martone et al., 2005). Accordingly, 
partial genetic ablation or antibody targeting of endoglin 
delays tumor growth in mouse models of cancer through 
inhibition of angiogenesis (Seon et al., 1997; Takahashi et al., 
2001a; Düwel et al., 2007; Seon et al., 2011). Collectively, 
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of neoplastic lesions to the angiogenic phase translated into a 
reduction of the number of overt tumors in mice partially 
deficient for endoglin (Fig. 2 b). In further support of an 
obstruction in the transition of pre-angiogenic lesions into 
tumors, 14/55 (25.5%) RIP1-Tag2;Eng+/ mice presented 
without any tumors, whereas only 1/22 (4.5%; P < 0.05, 
2-test) littermate control mice were tumor free. Nevertheless, 
the mean total tumor volume per mouse was not different 
between the groups (Fig. 2 c), indicating that a majority of 
the RIP1-Tag2;Eng+/ mice eventually adapted to the initial 
impairment in tripping the angiogenic switch. No compen-
satory up-regulation of endoglin mRNA or protein in en-
dothelial cells or other cell types was apparent in end-stage 
tumors from endoglin-deficient mice (unpublished data), sug-
gesting alternative evasive action by tumors harboring a ge-
netically stunted ability to initiate the angiogenic phase in 
the absence of endoglin.
Endoglin-deficient RIP1-Tag2 mice present  
with an increased number of hepatic metastases
Next, we sought to characterize the impact of blunted endo-
glin expression on the angiogenic and invasive program of 
PNET from RIP1-Tag2 mice. The vascular density of tumors 
and premalignant angiogenic lesions assessed by immuno-
staining for the luminal vessel marker podocalyxin (Horvat 
et al., 1986) was similar in PNET regardless of endoglin status 
(Fig. 2, d and e). Furthermore, the functionality of the end-
stage tumor vessels, inferred by study of the degree of perfu-
sion using fluorescein-coupled tomato lectin, was found to 
be unaffected by partial deficiency for endoglin in tumors 
(Fig. 2, f and g). The emergence of tumors resistant to treat-
ment with VEGFR-blocking agents is characterized by in-
creased metastatic spread consequential to a highly locally 
invasive phenotype (Casanovas et al., 2005; Pàez-Ribes et al., 
2009). Having documented that ablation of endoglin also 
gives rise to an adaptive response, we wanted to investigate 
whether evasive action against genetically impaired angio-
genesis also resulted in increased metastatic dissemination. 
The liver is the most frequent site for metastatic coloniza-
tion of PNET in human patients (Pavel et al., 2012). Strik-
ingly, RIP1-Tag2;Eng+/ mice presented with a threefold 
increased incidence of micrometastases expressing SV40 
T-Ag embedded in the liver parenchyma, as compared with 
RIP1-Tag2;Eng+/+ littermates (Fig. 2, h and i).
Increased metastatic spread in endoglin-deficient mice  
is an endothelial cell–autonomous event
To investigate whether tumor adaptation to genetic target-
ing of endoglin is an endothelial cell–autonomous event, 
we induced conditional ablation of both copies of the gene 
encoding endoglin specifically in endothelial cells through 
the use of tamoxifen injection of compound EngiKOe mice 
(Engfl/fl; Cdh5-CreERT2; Mahmoud et al., 2010). Injection 
of the mouse lung carcinoma cell line LLC in EngiKOe mice 
resulted in an initial delay in the establishment of tumors 
compared with tamoxifen-treated control Engfl/fl mice (day 6; 
endoglin-deficient RIP1-Tag2 mice harbored a reduced pro-
portion of angiogenic versus hyperplastic islets at 12 wk of 
age (RIP1-Tag2;Eng+/ mice, 30% vs. RIP1-Tag2;Eng+/+ mice, 
56%; P < 0.01, 2-test). Moreover, the blockade in transition 
Figure 1. Endoglin is expressed by endothelial cells during the  
angiogenic switch of PNET in RIP1-Tag2 mice. (a) Quantitative RT-PCR 
analysis of expression of endoglin during the different stages of tumori-
genic conversion in RIP1-Tag2 mice (a pool of material each derived from 
>10 mice was used for the analysis). Error bars depict SD. (b) Immunostain-
ing for CD31 and endoglin in PNET lesion from RIP1-Tag2 mice. (c) Immuno-
staining for the pericyte marker NG2 and endoglin in PNET lesion from 
RIP1-Tag2 mice. (b and c) Cell nuclei are shown with DAPI. The dashed line 
marks the tumor-exocrine pancreas boundary. Bars, 50 µm.
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Figure 2. Increased metastatic seeding of tumors in endoglin-deficient mice. (a–c) Quantification of number of angiogenic islets (a), num-
ber of tumors (b), and total tumor burden (c) in 12-wk-old RIP1-Tag2;Eng+/+ (n = 22) and RIP1-Tag2;Eng+/ mice (n = 55). (d and e) Immunostaining  
(d) and quantification (e) of total positively stained area for the vascular marker podocalyxin in PNETs from RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice. 
Analysis was performed using at least five mice per group. (f and g) Perfused vessels in PNETs from RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice 
visualized (f) and quantified (g) by fluorescein-labeled tomato lectin. The dashed line marks the tumor-exocrine pancreas boundary. Analysis was 
performed using three mice per group. (d and f) Cell nuclei are shown with DAPI. (h) Representative picture of hematoxylin-eosin staining (left) and 
immunostaining for SV40 T-antigen (T-Ag; right) of a micrometastatic liver lesion. The arrow inside the sinusoidal vessel marks metastatic lesion. 
(i) Quantification of micrometastatic foci in the liver of RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice at 12 wk of age. Error bars depict SD; n.s., 
not significantly different. Bars, 50 µm.
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immunostaining to lack endoglin expression (unpublished 
data). To further support the association between deficiency 
for endoglin and increased metastatic spread, we assessed 
the occurrence of lung metastases of LLC tumors grown in 
the EngiKOe mice. Indeed, mice with an induced endothelial 
cell–specific knockout of endoglin presented with a mean 
of threefold more metastatic foci in the lung than WT mice 
(Fig. 3 d). The mean size of the metastatic lesions did not 
differ significantly between the genotypes, indicating that 
metastatic seeding, rather than growth rate, was affected in 
Fig. 3 a), in agreement with previous studies (Düwel et al., 
2007). However, similar to the retardation of PNET devel-
opment in RIP1-Tag2 mice, LLC tumors in EngiKOe mice 
eventually caught up, and at the conclusion of the experi-
ment, tumor volume was indistinguishable from that of 
tumors in the control groups (day 18; Fig. 3 a). Consis-
tently, the delay in establishment of LLC-RFP tumors in 
EngiKOe mice was mirrored in an initial, but transient, impedi-
ment to activate tumor vascularization in EngiKOe mice (Fig. 3, 
b and c). Tumors grown in EngiKOe mice were confirmed by 
Figure 3. Increased metastatic seeding in 
endoglin-deficient mice is an endothelial 
cell–autonomous event. (a) In vivo tumor 
volume of subcutaneously injected LLC-RFP 
cells at 6 and 18 d in control (n = 7 and n = 19, 
respectively), tamoxifen-treated control  
(n = 7 and n = 11, respectively), and EngiKOe 
(n = 9 and n = 15, respectively) mice. (b and c) 
Quantification (b) and immunostaining (c) of 
vessel density of LLC-RFP tumors using CD31 
during initial phases of tumor development 
and at the endpoint of the experiment in 
control (n = 7 and n = 19, respectively), 
tamoxifen-treated controls (n = 7 and n = 11, 
respectively), and EngiKOe (n = 9 and n = 15, 
respectively) mice. (d) Representative picture 
and quantification of lung metastases using 
fluorescent imaging of RFP-tagged LLC cells 
(LLC-RFP) in control (n = 19), tamoxifen-
treated control (n = 11) or EngiKOe (n = 15) 
mice with established subcutaneous tumors. 
A subset of mice (n = 8, 6, and 6, respectively) 
was also analyzed for the mean size of meta-
static lesions. The horizontal lines represent 
median. Statistical analysis was performed 
using the Mann-Whitney U test. (e) Quantifi-
cation of lung metastases of LLC-RFP tumors 
established subcutaneously in Eng+/+ (n = 11) 
or Eng+/ (n = 9) mice. (f) Representative pic-
ture of hematoxylin-eosin staining of a mi-
crometastatic lung lesion from EO771 tumors. 
Quantification of micrometastatic foci in the 
lung of EO771-bearing Eng+/+ (n = 5) and 
Eng+/ (n = 5) mice. (g) Quantification of lung 
metastases from EO771 tumors established 
subcutaneously in control (n = 8), tamoxifen-
treated control (Tam; n = 8), or EngiKOe (n = 8) 
mice. Error bars depict SD. Bars, 50 µm.
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reduced endoglin signaling counteracted the more malignant 
phenotype of tumor cells from mice treated with anti-VEGF 
therapy (Fig. 4 b). To determine whether the synergy between 
endoglin deficiency and AG-028262 was a direct effect of 
inhibition of VEGF signaling, we made use of the VEGFR2-
neutralizing antibody DC101. Similar to our earlier observa-
tions, RIP1-Tag2;Eng+/ mice maintained sensitivity toward 
DC101, both in terms of delayed tumor growth and meta-
static dissemination (Fig. 4, a and b).
The findings in the RIP1-Tag2 model were validated by 
the fact that EO771 tumors grown orthotopically in the 
mammary fat pad of Eng+/ mice had a similarly heightened 
sensitivity to anti-VEGF therapy and a concomitantly lowered 
incidence of lung metastases and decreased vascular density 
after AG-028262 therapy, compared with WT littermates 
(Fig. 4, d and e; and not depicted). Likewise, EngiKOe mice 
carrying subcutaneous LLC tumors presented with a dramati-
cally reduced size of metastatic lesions in the lung compared 
with control mice after treatment with AG-028262, despite 
exhibiting similar growth rates (Fig. 4, f and g; and not de-
picted). Thus, concurrent attenuation of endoglin- and VEGF-
induced signaling provided effective and long-term control 
of metastatic dissemination.
Endoglin deficiency leads to facilitated  
tumor cell intravasation
We sought to determine the mechanism for the increased 
propensity for hematogenous spread of tumors in endoglin-
deficient mice. No significant difference was found in the 
incidence of locally invasive tumors between PNETs from 
RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice as assessed by 
histopathological scoring (unpublished data). In addition, no 
endoglin-dependent hypoxia or alterations in the tumor-wide 
expression of >40 genes involved in the metastatic or angio-
genic program of tumors were noted, as assessed by pimonida-
zole adduct formation (unpublished data) and by analysis of 
global gene expression (unpublished data), respectively. Next, 
with the purpose of evaluating whether endothelial cells with 
diminished endoglin expression are permissive to tumor cell 
transmigration to a greater extent than their WT counterparts, 
we established an in vitro transwell assay. An endothelial cell 
line stably expressing a short hairpin RNA targeting endoglin 
(bEnd3.1/shEng) was seeded onto membranes in trans-well 
inserts and allowed to form a monolayer. Next, prelabeled 
TC-3 tumor cells derived from a PNET of a RIP1-Tag2 
mouse (Efrat et al., 1988) or EO771 cells were seeded on 
top of the endothelial cells, and malignant cell transmigra-
tion through the endothelial cell layer to the lower chamber 
was scored as a proxy for tumor cell intra-/extravasation. 
Compared with endothelial cells harboring a control vector, 
bEnd3.1/shEng allowed significantly more tumor cells to 
pass through the endothelial cell layer, indicating that endoglin 
is important for maintaining the integrity of the endothelial 
cell barrier (Fig. 5 a). Likewise, 4-OH-tamoxifen–induced 
knockout of endoglin from microvascular lung endothelial 
cells isolated from Engfl/fl; Rosa26-CreERT mice carrying the 
endoglin-deficient mice (Fig. 3 d). LLC tumors injected 
subcutaneously into Eng+/ mice similarly gave rise to a sig-
nificantly higher number of lung metastases than tumors 
grown in WT littermates, despite exhibiting a comparable 
growth rate (Fig. 3 e and not depicted).
To investigate the generality of the increased metastatic 
spread in tumors grown in endoglin-deficient mice, we es-
tablished mouse mammary tumors by orthotopic implanta-
tion of EO771 cells (Casey et al., 1951) into the inguinal fat 
pad of Eng+/ mice or WT littermates. EO771 tumors were 
intrinsically resistant to the lowered expression of endoglin in 
terms of growth rate and vascular density (unpublished data). 
In contrast, lung metastases originating from EO771 tumors 
were 2.1-fold more prevalent in Eng+/ mice compared with 
Eng+/+ mice (Fig. 3 f). In further support, the frequency of 
lung metastases originating from EO771 tumors injected or-
thotopically into the mammary fat pad of EngiKOe mice was 
significantly increased compared with littermate control mice 
(Fig. 3 g), with no apparent effect observed on the primary 
tumor growth or vascular density at the end of the experi-
ment (not depicted). Collectively, data from five different 
mouse models of cancer representing three distinct malignant 
diseases demonstrate that a reduced gene dosage of endoglin 
in endothelial cells provokes the outgrowth of tumors with 
an increased propensity to seed distant metastases.
Endoglin heterozygosity maintains tumors  
in a sensitive state to VEGF inhibition
The compound tumor phenotype observed in mice with 
loss of endoglin expression is remarkably similar to that ob-
served in preclinical studies for tumors resistant to anti-VEGF 
therapy. Although the expression level of VEGF pathway 
members was not altered in angiogenic islets or tumors from 
endoglin-deficient RIP1-Tag2 mice (unpublished data), 
pharmacological or genetic targeting of endoglin interferes 
with VEGF-induced angiogenesis, indicating cross talk on a 
molecular level (unpublished data; Castonguay et al., 2011). 
Therefore, we decided to evaluate the effect of the absence of 
endoglin on VEGF-blunted neovascularization. First, we 
treated RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice with 
the selective VEGFR tyrosine kinase inhibitor AG-028262 
(Zou, H.Y. et al. 2004. Annual Meeting of the American 
Association for Cancer Research. Abstr. 2578). AG-028262 
effectively blocked PNET growth in the RIP1-Tag2 tumor 
model when supplied in preventive short-term trials (un-
published data). However, in agreement with earlier studies 
(Casanovas et al., 2005; Pàez-Ribes et al., 2009), long-term 
therapy of RIP1-Tag2 mice with VEGF-blocking agents 
was not effective because of the emergence of refractory 
tumors supporting increased metastatic dissemination to the 
liver (Fig. 4, a and b). In striking contrast, PNETs of RIP1-
Tag2;Eng+/ mice maintained sensitivity to AG-028262, as 
assessed by tumor size and vessel density, even during pro-
longed therapy (Fig. 4, a and c). Importantly, metastatic colo-
nization of the liver was not increased after administration 
of AG-028262 to endoglin-deficient mice, indicating that 
JEM Vol. 210, No. 3 
Article
569
Figure 4. Endoglin deficiency maintains tumors in a sensitive state to VEGF inhibition. (a) Total tumor burden of RIP1-Tag2;Eng+/+ and RIP1-
Tag2;Eng+/ mice at 13 wk of age after 3 wk of treatment with vehicle (n = 6 and n = 5, respectively), the small molecule VEGFR inhibitor AG-028262 
(n = 9 and n = 5, respectively), or the VEGFR2-neutralizing antibody DC101 (n = 3 in each group). The data shown are representative of two indepen-
dent experiments. (b) Quantification of micrometastatic PNET foci in the liver of RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice at 13 wk of age after  
3 wk of treatment with vehicle (n = 4 in each group), AG-028262 (n = 4 in each group), or DC101 (n = 3 in each group). (c) Quantification of total 
positively stained area for the vascular marker podocalyxin in PNET from RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice after 3 wk treatment with  
vehicle or AG-028262. (d and e) In vivo growth rate (d) and quantification of micrometastatic lung foci (e) of orthotopically implanted EO771 mam-
mary tumors in Eng+/+ and Eng+/ mice during treatment with control or AG-028262 (n = 5–11). Data from control mice are reproduced from Fig. 3 f 
to allow easy comparison. (f and g) Representative image (f) and quantification (g) of metastatic foci of LLC-RFP tumors in the lungs of EngiKOe mice 
treated with vehicle or AG-028262. Error bars depict SD.
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In PNETs from WT RIP1-Tag2 mice, CD31 was robustly 
expressed by endothelial cells of both large vessels and small 
neo-angiogenic capillaries and sprouts (Fig. 6 a). Partial loss of 
endoglin in RIP1-Tag2;Eng+/ mice resulted in a consider-
able decrease of strongly CD31+ small capillaries in PNETs 
(Fig. 6, a and b). Double immunostaining for the endothelial 
cell marker podocalyxin and CD31 revealed that small cali-
ber podocalyxin+ vessels of tumors from RIP1-Tag2;Eng+/ 
mice were only weakly expressing CD31 (Fig. 6 c). Endoglin-
 deficient endothelial cells that retained close to normal pro-
tein levels of CD31 exhibited a more diffuse localization of 
CD31 and were partially detached from the podocalyxin+ 
endothelial cells (Fig. 6 d), in agreement with an earlier 
study describing the phenotype of endothelial progenitor 
cells undergoing TGF-–mediated EndMT (Moonen et al., 
2010). EndMT, a process of hitherto unknown functional 
importance in tumors, involves loss of endothelial marker 
expression, such as CD31, concomitant with an increase in 
mesenchymal marker expression, such as –smooth muscle 
actin (-SMA; Zeisberg et al., 2007). To investigate whether 
endothelial cells adopted a more mesenchymal state in endoglin-
deficient tumors, we performed immunostaining for -SMA. 
Indeed, RIP1-Tag2;Eng+/ mice presented with PNETs with 
an increase of vessel-associated -SMA+ cells (Fig. 6 e and 
not depicted). Furthermore, a subset of vessels appeared com-
posed of cells co-expressing the endothelial cell marker podo-
calyxin and the mesenchymal marker -SMA, indicative of 
ongoing EndMT (Fig. 6 e and not depicted). High-power 
confocal microscopy also revealed diminution and redistribu-
tion of CD31 into a more diffuse localization in endothelial 
cells, accompanied by an increased abundance of -SMA im-
munoreactivity inside or juxtaposed to the endothelium in 
PNETs from RIP1-Tag2;Eng+/ mice (Fig. 6 f and not de-
picted). The vasculature of RIP1-Tag2;Eng+/ mice was fur-
ther invested by an increased number of cells expressing the 
mural cell marker NG2 (Fig. 6 g) Likewise, the vasculature of 
EO771 tumors grown in Eng+/ mice were invested with a 
2.2-fold higher abundance of cells expressing mesenchymal 
markers such as -SMA, cells which to a large extent also co-
expressed the endothelial cell marker podocalyxin (Fig. 6, 
h and i). Thus, Eng+/ mice present with a subset of malignant 
lesions exhibiting a vasculature composed of cells with a 
mixed endothelial and mesenchymal identity.
Endoglin-deficient tumor endothelial cells express  
Twist and are more prone to undergo EndMT
In seeking additional evidence for the manifestation of 
EndMT in endoglin-deficient endothelial cells in vivo, we 
isolated tumor endothelial cells from RIP1-Tag2 mice. Our 
analyses demonstrated a dramatically increased content of the 
mRNA for Twist, a transcriptional regulator known to be a 
key activator of EndMT, in isolated endothelial cells from 
tumors of RIP1-Tag2;Eng+/ mice, compared with tumors 
from WT littermates (Fig. 7 a). The up-regulation of Twist 
in endoglin-deficient endothelial cells was evident neither in 
liver endothelial cells nor in nonendothelial cells of tumors 
Immortomouse transgene facilitated transmigration of LLC-
RFP cells across an endothelial monolayer, compared with 
parental, noninduced cells (termed MLEC;Eng/ and MLEC; 
Eng+/+, respectively; Fig. 5 a).
The observed increased colonization of metastases in en-
doglin-deficient mice can be causal to an improved seeding 
of tumor cells from the primary site into the circulation, a fa-
cilitated extravasation of tumor cells into the metastatic site, 
or both. To distinguish between these possibilities, we as-
sessed the number of circulating malignant cells, as well as the 
propensity of intravenously injected tumor cells to extrava-
sate in endoglin-deficient mice. We found that whole blood 
of RIP1-Tag2;Eng+/ mice contained a 57% higher abun-
dance of the transgenic transcript for SV40 T-Ag than RIP1-
Tag2;Eng+/+ mice, suggesting that an increased number of 
tumor cells were seeded into the circulation of endoglin-
 deficient mice by primary PNETs (Fig. 5 b). Ultrastructural 
analysis of tumor capillaries from RIP1-Tag2 mice demon-
strated no gross differences in the architecture of the vessels or 
overt malformations in endothelial cell junctions in endoglin-
deficient mice, suggesting that the increased abundance of 
tumor cells in the circulation of RIP1-Tag2;Eng+/ mice was 
the result of a regulated process and not simply of a physical 
loss of endothelial barrier patency (Fig. 5 c). In keeping with 
this proposition, the tumor vasculature in RIP1-Tag2;Eng+/ 
mice was found neither to be leakier to fluorescently labeled 
small molecules (1 kD cadaverine) or macromolecules (70 kD 
dextran; Fig. 5 d and not depicted) nor to exhibit a decreased 
perfusion grade (Fig. 2, f and g). Likewise, no difference in 
leakiness to dextran was observed in the vasculature of lungs 
of EngiKOe mice after induction of endoglin deficiency (un-
published data).
No increased transmigration of tumor cells into the liver 
was found after intravenous injection of prelabeled TC-3 
cells into nontumor-bearing endoglin-deficient mice, consis-
tent with the negligible level of endoglin expression by liver 
sinusoids (Fig. 5, e and f; and not depicted). In contrast, when 
LLC tumor cells were introduced into the blood stream of 
EngiKOe mice, 13-fold more metastatic foci were found in the 
lungs 2 wk later compared with control mice, indicating that 
in this tumor model the endoglin-deficient vasculature was 
defective in its ability to contain tumor cells in the lung cir-
culation (Fig. 5 g and not depicted). Notably, lung capillaries 
were found to readily express endoglin in WT mice (Fig. 5 f). 
Thus, augmented metastatic colonization in endoglin-deficient 
mice was found to be consequential to an increased endothe-
lial cell leniency toward malignant cell intra- and/or extrava-
sation, indicative of a role for endoglin in regulating cellular 
transmigration across the endothelial barrier.
Facilitated tumor cell intravasation is accompanied  
by EndMT in endoglin-deficient tumors
To gain insight into the underlying cause of the facilitated 
transmigration of tumor cells across the endoglin-deficient 
endothelial cell barrier, we investigated the junctional integrity 
of the tumor vasculature using immunostaining for CD31. 
JEM Vol. 210, No. 3 
Article
571
Figure 5. The increased metastatic seeding in endoglin-deficient mice is a result of disruption of the endothelial cell barrier. (a) Transmi-
gration of TC-3 cells derived from a PNET in a RIP1-Tag2 mouse, EO771 cells, or LLC-RFP cells through a monolayer of bEnd3.1 endothelial cells 
expressing either shRNA-endoglin or control vector or through a monolayer of primary mouse lung endothelial cells isolated from EngiKOe mice carry-
ing the Immortomouse transgene (MLEC). The mean of two to three independent experiments is shown. (b) Quantitative RT-PCR detection of SV40  
T-Ag transcripts in whole blood from RIP1-Tag2;Eng+/+ (n = 10) and RIP1-Tag2;Eng+/ (n = 5) mice. (c) Electron micrographic views of transversely cut 
tumor microvessels in RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice. Interendothelial junctions are indicated from the luminal aspect (long arrows). 
Continuous periendothelial basal laminae (short arrows) invest cytoplasmic strands of pericytes (white asterisks). tc, tumor cell. (d) Detection of  
extravasated fluorescently labeled 70 kD dextran and immunostaining for podocalyxin of PNETs from RIP1-Tag2;Eng+/+ mice and RIP1-Tag2;Eng+/ 
excised 4 min after injection of dextran. (e) Quantification of extravasated TC-3 cell labeled with a fluorescent tracer (green) in the liver parenchyma 
from Eng+/+ (n = 4) and Eng+/ (n = 3) mice 24 h after tail vein injection. (f) Immunohistochemical detection of endoglin in liver sinusoidal endothelial 
cells and lung capillaries. Cell nuclei are shown with DAPI. Arrows point out sinusoidal and lung capillaries. hbv, hepatic blood vessel; br, bronchiolus. 
(g) Quantification of LLC-RFP metastatic foci in the lung 15 d after tail vein injection in WT tamoxifen-treated (n = 9) and EngiKOe (n = 8). Horizontal 
lines represent median. Statistical analysis was performed using the Mann-Whitney U test. Error bars depict SD. Bars: (c) 1 µm; (d and f) 50 µm.
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Figure 6. Reduced endoglin expression gives rise to hallmarks of EndMT in tumors in vivo. (a) Immunostaining for CD31 of PNETs from 12-wk-old 
RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice. The dashed line marks the tumor-exocrine pancreas boundary. (b) Quantification of vessels with high CD31 
expression in PNET lesions from RIP1-Tag2;Eng+/+ (n = 3) and RIP1-Tag2;Eng+/ (n = 4) mice. (c and d) Immunostaining for podocalyxin and CD31 of PNET 
lesions from 12-wk-old RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice. (e) Immunostaining for podocalyxin and -SMA of PNET lesions from RIP1-Tag2;Eng+/+ 
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selective TGF- type I receptor inhibitor LY364947 nor-
malized the endothelial barrier properties of MLEC;Eng/ 
cells (Fig. 7 g). In summary, consequential to reduced expres-
sion of endoglin, tumor endothelial cells up-regulate Twist 
and other ALK5 target genes, leading to EndMT and facili-
tated tumor cell transfer across the endothelial barrier.
DISCUSSION
The functional importance of EndMT in tumors has until 
now not been well understood. Our study identifies EndMT 
as a novel enabling factor for metastatic dissemination by fa-
cilitating tumor cell intra- and/or extravasation. Thus, in ad-
dition to promoting metastatic spread by direct stimulation of 
epithelial-to-mesenchymal transition of tumor cells (Padua 
and Massagué, 2009), TGF- acts to assist transmigration of 
malignant cells across the endothelial cell barrier by inducing 
EndMT. In the context of metastatic dissemination, efforts to 
find therapeutic targets to reduce the spread of tumors have 
mostly focused on targeting the invasive properties of the 
malignant cell by searching for genetic alterations driving the 
progression of cancer into a systemic disease (Nguyen et al., 
2009). Here, the properties of endothelial cells are high-
lighted as important tumor cell nonautonomous regulators 
of metastatic dissemination. It may be that genetic or molecu-
lar signaling events promoted by the cross talk between the 
tumor and the stroma interact to create a confined milieu fa-
voring metastatic dissemination; such events may prove dif-
ficult to uncover using global analyses of tumor materials. 
Thus, further studies should aim at identifying local regula-
tors of EndMT and tumor endothelial cell barrier properties 
to develop drugs that promote sealing of the intrinsic vascular 
barricade to prevent cancer spread.
The accelerated transition of endothelial cells with an en-
gineered low expression of endoglin into a mesenchymal state, 
and the increased appearance of cells expressing -SMA and 
NG2 as constituents of blood vessels in tumors deficient for 
endoglin, suggest that EndMT may also give rise to pericyte-
like cells within tumors (Franco et al., 2011b). The aberrant 
occurrence of -SMA+ perivascular cells has been noted pre-
viously in conjunction with increased metastatic formation in 
RIP1-Tag2 mice deficient for a single or both copies of the 
gene encoding neural cell adhesion molecule (NCAM; Xian 
et al., 2006), raising the question of whether diminished ex-
pression of NCAM is part of the EndMT phenotype. Further-
more, we and others have recently identified an increased 
profusion of perivascular cells expressing -SMA as a particu-
lar feature of a subset of tumors that are refractory to anti-
VEGF therapy in mouse models of PNET and malignant 
melanoma, respectively (Helfrich et al., 2010; Franco et al., 
2011a), although it was not investigated whether EndMT was 
from RIP1-Tag2 mice, indicating that induction of EndMT 
is a specific trait of the PNET endothelium after genetic abla-
tion of endoglin (Fig. 7 a and not depicted). Stimulation with 
TGF- readily induced EndMT in endothelial cells in vitro, 
as indicated by a morphological switch from the typical cob-
blestone appearance of endothelial cells into an elongated and 
spindle-like shape (Fig. 7 b). To investigate whether loss of 
endoglin expression was sufficient to activate the program 
for EndMT, we again made use of the bEnd3.1/shEng cells 
with a diminished endoglin protein expression. Knockdown 
of endoglin resulted in an increased sensitivity of endothelial 
cells to undergo EndMT both at baseline conditions or after 
stimulation with TGF-, as indicated by loss of CD31 and 
gain of -SMA protein (Fig. 7, c and d). In contrast, inhibi-
tion of VEGF signaling by DC101 did not affect TGF-–
 induced EndMT (unpublished data). In further support of 
the proposition that endoglin deficiency facilitated induc-
tion of EndMT, MLEC;Eng/ cells exhibited an elongated 
morphology compared with MLEC;Eng+/+ cells (unpublished 
data). Stable knockdown of Twist using lentiviral delivery 
of shRNA in MLEC;Eng+/+ or MLEC;Eng/ cells pre-
vented TGF-induced EndMT (unpublished data), indi-
cating a pivotal role for Twist as a downstream mediator of 
EndMT in the endoglin-deficient state. Twist knockdown in 
MLEC;Eng/ cells also normalized the rate of transendothe-
lial migration of TC-3 cells (Fig. 7 e), indicating that Twist-
induced EndMT of endoglin-deficient cells is underlying the 
defect in cellular barrier properties. Moreover, EndMT in-
duced by TGF- stimulation of MS1 pancreatic islet endo-
thelial cells resulted in a greatly facilitated transmigration of 
TC-3 cells (Fig. 7 f), strengthening the proposition that in-
duction of TGF-–mediated EndMT is paralleled by a weak-
ened endothelial cell barrier to tumor cell transmigration. 
Knockdown of CD31 proved sufficient to enhance trans-
endothelial tumor cell migration by either TC-3 or EO771 
cells (unpublished data), suggesting that the EndMT and con-
sequential redistribution/reduced abundance of CD31 facili-
tated cellular transfer across the endothelium. To understand 
the molecular mechanism behind the observed EndMT in 
endoglin-deficient tumor vessels, we probed signaling down-
stream of the TGF- type I receptor ALK5 in isolated PNET 
endothelial cells. ALK5 signaling is known to mediate EndMT 
(Medici et al., 2010; Moonen et al., 2010; Egorova et al., 
2011) and to be antagonized by the action of endoglin (Lebrin 
et al., 2004; Blanco et al., 2005). In agreement with these 
previous studies, loss of one copy of the endoglin gene re-
sulted in improved transcriptional activation of prototypical 
ALK5 target genes in vivo in endothelial cells isolated from 
PNETs of RIP1-Tag2;Eng+/ mice (Fig. 7 g), indicative of a 
molecular contribution of ALK5 to the EndMT. Indeed, the 
and RIP1-Tag2;Eng+/ mice. (f) Representative confocal micrograph of immunostaining for CD31 and -SMA of PNET lesion from 12-wk-old RIP1-Tag2;Eng+/+ 
and RIP1-Tag2;Eng+/ mice. (g) Immunostaining and quantification of NG2 and CD31 of sections of PNET from 12-wk-old RIP1-Tag2 mice. (a, e, and g) Cell 
nuclei are shown with DAPI. (h) Immunostaining for podocalyxin and -SMA of EO771 tumors grown in Eng+/+ or Eng+/ mice.(i) Quantification of -SMA+ 
vessels in EO771 tumors from Eng+/+ (n = 4) and Eng+/ (n = 4) mice. Error bars depict SD. Bars: (a) Bars, 100 µm; (c–h) 50 µm.
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Figure 7. Reduced expression of endoglin in endothelial cells facilitates EndMT and tumor cell transmigration. (a) Quantitative RT-PCR for 
Twist in isolated endothelial cells or nonendothelial cells (other cells) from PNETs of 12-wk-old RIP1-Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice. A represen-
tative experiment using a pool of material derived from more than six mice per group is shown. (b) Micrograph of bEnd3.1 endothelial cells stimulated 
with TGF- for 48 h. (c) Western blot of endoglin, -SMA, and CD31 in bEnd3.1 cells expressing either shRNA-endoglin or empty vector stimulated with 
TGF-. -Actin served as a loading control. The dividing line marks duplicate lanes that were removed. (d) Immunostaining for CD31 and -SMA of 
bEnd3.1/shRNA-endoglin or control cells with and without TGF- stimulation. (e) Transmigration of TC-3 cells through a monolayer of MLEC either 
induced or noninduced to knock out the gene for endoglin by treatment with 4-OH-tamoxifen and infected with a lentiviral control construct (shCtrl) or 
shTwist construct. The mean of two independent experiments is shown. (f) Transmigration of TC-3 cells through a monolayer of MS1 pancreatic islet 
endothelial cells stimulated with TGF-. The mean of three independent experiments is shown. (g) Quantitative RT-PCR for the ALK5 target genes fibro-
nectin (Fn), plasminogen activator inhibitor-1 (PAI-1), and platelet-derived growth factor B (PDGF-B). A pool of endothelial cell–specific genes (VE-cadherin, 
CD31, and VEGFR-2) was used as a reference. The mean of two independent experiments is shown (a pool of material derived from more than six mice 
per group was used for the analysis). (h) Transmigration of -TC3 cells through a monolayer of MLEC either induced or noninduced to knock out the gene 
for endoglin by treatment with 4-OH-tamoxifen and in the presence of 1 µM of the ALK5 inhibitor LY364947. The mean of two independent experiments 
is shown. Error bars depict SD. Bars: (b) 50 µm; (d) 20 µm.
JEM Vol. 210, No. 3 
Article
575
It is interesting to note that genetic loss of a single copy of 
the gene encoding endoglin was sufficient to induce evasive 
mechanisms to circumvent the impairment in angiogenesis 
and cause increased metastatic spread. Thus, one may specu-
late that cancer patients harboring germline-transmitted hy-
pomorphic alleles of prototypical angiogenic regulators may 
be predisposed to developing metastatic disease by induction 
of tumor cell autonomous and/or nonautonomous evasive 
programs to the genetically impaired angiogenic response. 
Efforts to identify such high-risk patient groups are highly 
warranted. Likewise, the observed breakdown of the endo-
thelial barrier to metastatic spread in mice lacking one copy 
of the endoglin gene holds significance for patients suffering 
from the syndrome HHT-1, caused by functional heterozy-
gosity for endoglin. Epidemiological studies of the preva-
lence and prognosis of cancer for HHT-1 patients are difficult 
to perform as a result of the low incidence in the popula-
tion. However, special care should be taken to follow up 
HHT-1 patients afflicted by malignant disease, as our study 
indicates that their prognosis may be comparatively poor. 
Interestingly, HHT patients are reported to exhibit increased 
serum levels of  VEGF-A (Sadick et al., 2005, 2008). Collec-
tively with the synergistic interaction of VEGF inhibition 
and endoglin deficiency observed in the present study, this 
suggests that tumors of HHT-1 patients may be exquisitely 
sensitive to drugs incorporating inhibitory action against 
VEGFRs. Although solitary blockade of angiogenic drivers 
through targeting of  VEGF or endoglin ultimately may lead 
to therapeutic refractoriness characterized by increased meta-
static spread, concurrent targeting of multiple pathways should 
offer increased efficacy. Thus, we conclude that combinations 
or cocktails of drugs impinging on distinct signaling pathways 
in the angiogenic response may prove to efficiently delay the 
onset of therapy-induced resistance in cancer.
MATERIALS AND METHODS
RNA isolation and quantitative RT-PCR. Total RNA was isolated 
using the RNeasy kit (QIAGEN) according to the manufacturer’s instruc-
tions, followed by cDNA synthesis of total RNA using iScript (Bio-Rad 
Laboratories). Total RNA from whole blood was purified by the RiboPure-
Blood RNA Isolation kit (Ambion). Quantitative PCR was performed using 
the QuantiMix SYBR green kit (BioTools) on a Rotorgene 6000 (QIAGEN) 
in triplicates. Total RNA from normal, hyperplastic, angiogenic, and tumor-
ous pancreatic islets was a gift from P. Olsen (Pfizer, La Jolla, CA) and 
D. Hanahan (École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland). 
Expression levels were calculated relative to the ribosomal reference gene 
RPL19 as 100 × 2Ct. For primer sequences for RPL19, endoglin, PAI-1, 
PDGFB, CD31, and VE-cadherin, see Cunha et al. (2010); for VEGFR2, 
see Hagberg et al. (2010); for Twist, see Yang et al. (2004); primers for fi-
bronectin were purchased from QIAGEN (QT00135758); and primers for 
SV40 T-Ag were 5-GGAAAGTCCTTGGGGTCTTC-3 (forward) and 
5-CTGACTTTGGAGGCTTCTGG-3 (reverse).
Tissue preparation, histology, and immunostaining. Mice were heart 
perfused with PBS followed by 2% paraformaldehyde. For paraffin embed-
ding, organs were postfixed in 2% paraformaldehyde at 4°C overnight. For 
cryopreservation, tumors and pancreata were kept in 30% sucrose at 4°C over-
night, followed by embedding in cryosectioning media. Frozen sections were 
fixed in cold acetone, followed by blocking using serum-free protein block 
evident under these conditions. Although the loss of endothelial 
cell identity through down-regulation of endoglin and CD31 
correlated with an increased leniency toward tumor cell trans-
migration, the rate of vascular perfusion or the extent of leak-
age of molecular tracers into the tumor parenchyma was not 
altered, in contrast to a recent study demonstrating enhanced 
vascular permeability in the colon of Eng+/ mice as a result of 
increased secretion of VEGF (Jerkic et al., 2010). Collec-
tively with the fact that the ultrastructure of endoglin-deficient 
tumor capillaries was seemingly normal, our findings suggest 
that tumor cells transmigrate across the endothelium through 
a controlled process and not simply by using physical gaps in 
the abnormal tumor vasculature, a conclusion which raises 
the possibility of developing antimetastatic drugs that inter-
fere with tumor cell intra- and extravasation. Future studies 
should address whether tumor cells use similar mechanisms 
for endothelial transmigration as immune cells and whether 
endothelial cells having undergone EndMT are also more 
permissive to inflammatory cell transmigration. Indeed, mice 
deficient for CD31 exhibit a facilitated transendothelial mi-
gration of immune cells, and engagement of CD31 on endothe-
lial cells inhibits ICAM-1–induced cytoskeletal rearrangements 
associated with immune cell trafficking (Graesser et al., 2002; 
Couty et al., 2007).
Apart from inducing EndMT, TGF- exerts a wide vari-
ety of effects on endothelial cells depending on the molecu-
lar context (Pardali et al., 2010; Cunha and Pietras, 2011). 
Recent work demonstrates that genetic or pharmacological 
blockade of the endothelial cell–restricted TGF- type I 
receptor ALK1 inhibits tumor angiogenesis and growth 
(Cunha et al., 2010; Mitchell et al., 2010; Hu-Lowe et al., 
2011). No overt resistance to the blockade of ALK1 was re-
ported in these studies, but long-term investigations are 
warranted to make conclusive statements. Targeting of endo-
glin by genetic, pharmacological, or immunological means 
consistently diminishes tumor angiogenesis, thereby delay-
ing tumor growth in a range of subcutaneously injected 
models (Seon et al., 2011). Moreover, high expression of en-
doglin in the tumor microvasculature, as judged by immuno-
staining, is associated with a poor patient outcome in different 
malignancies. As a result of these findings, the human chime-
ric antibody TRC105 against endoglin is currently being 
clinically developed. Despite being an attractive and preclini-
cally proven drug target for antiangiogenic therapy of tumors, 
our data indicate that long-term therapeutic protocols in-
volving pharmacological inhibition of endoglin should be 
approached with caution (although we acknowledge the po-
tential pitfalls in translating genetic studies into conclusions 
about pharmacological interventions). In support of this prop-
osition, and as a human correlate to our findings, high serum 
levels of a soluble form of endoglin, ostensibly an inhibitor 
of endoglin action, produced by the release of the extracel-
lular domain through cleavage by matrix metalloprotease-14 
(Hawinkels et al., 2010), is correlated to the occurrence of 
metastatic disease in breast and colon carcinoma patients 
(Takahashi et al., 2001b).
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LLC-RFP tumor model were removed for analysis of metastases with a fluor-
escence stereomicroscope at 18 d after subdermal inoculation or 15 d after tail 
vein injection of 2.5 × 105 LLC-RFP cells to examine extravasation.
Therapeutic trials. AG-028262 (a gift from D. Hu-Lowe, Pfizer) was 
dissolved in 0.5% carboxymethylcellulose and was administered at a dose 
of 75 mg/kg once daily by oral gavage. The effective dose of AG-028262 
was 54.8 mg/kg after correction for the fraction of active drug contained 
in the particular batch used (73.1% active compound). DC101 was deliv-
ered intraperitoneally twice weekly at 1 mg/mouse and injection. RIP1-
Tag2;Eng+/+ and RIP1-Tag2;Eng+/ mice were treated with vehicle, 
AG-028262, or DC101 from 10 wk of age for 3 wk. Mice carrying EO771 
tumors were treated with AG-028262 or vehicle for 2 wk starting 7 d 
after establishment.
Tumor cell transmigration assay. 60,000 bEND.3 cells or 75.000 MS1 
cells were seeded in 8-µm pore inserts and allowed to form a monolayer. 
TC-3 or EO771 cells were labeled in green using the Vybrant CFDA SE 
Cell Tracer kit (Invitrogen), and 500,000 labeled tumor cells were seeded 
over the endothelial cell monolayer and allowed to transmigrate for 24 h. 
The inserts were fixed, cut, and mounted on a slide with DAPI-containing 
mounting medium. The transmigration index was assessed by quantifying 
10–12 high-power fields per insert and was expressed as the percentage of 
green-positive pixels per total number of DAPI-positive pixels.
Endothelial cell isolation. RIP1-Tag2 mice (more than six mice per isola-
tion) were heart perfused with PBS, and tumors were dissected and minced 
and digested in 0.05 g collagenase type II (Worthington), 0.05 g collage-
nase IV (Invitrogen), and 0.01 g DNase I (Sigma-Aldrich) for 15 min at 37°C 
with vigorous stirring. After passing tissue through a 70-µm strainer, the so-
lution was centrifuged at 1.2 krpm at 4°C for 8 min. The pellet was dissolved 
in 10 ml PharmLyse buffer for 10 min at room temperature, resuspended in 
1 ml buffer and 50 µl CD31-coated beads (Biotin-conjugated MEC13.3 
CD31 antibody [BD] and CELLection biotin binder kit [Invitrogen]), and 
incubated end over end at 4°C for 30 min. Using a magnetic bead collector, 
beads were washed eight times. Supernatant from the first collection was 
designated the other cell fraction. Using quantitative RT-PCR, an endothe-
lial cell enrichment index was calculated by correlating the relative abun-
dance of the endothelial cell markers CD31, VE-cadherin, and VEGFR-2 
for each preparation.
Statistical analysis. Unless specifically stated to the contrary, all measure-
ments are depicted as mean ± SD. Statistical analyses were, unless otherwise 
noted, performed using an unpaired two-tailed Student’s t test. Statistical analy-
sis of the frequency of angiogenic islets or tumor-free mice was performed 
using a 2-test. Statistical significance was considered using  = 0.05.
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(DAKO) or 0.5% blocking reagent in PBS (NEN Life Science Products) for 
>90 min at room temperature. Primary antibodies directed against CD31 
(clone 2H8; dilution 1:200; Millipore), Endoglin (clone MJ7/18; dilution 
1:100 to 1:200; eBioscience), Podocalyxin (dilution 1:100; AF1556; R&D 
Systems), CD31 (MEC13.3; dilution 1:100 or 1:25 for LLC-RFP tumors; 
BD), -SMA–Cy3 (clone 1A4; dilution 1:100; Sigma-Aldrich), and NG2 
(AB5320; dilution 1:400; Millipore) were incubated overnight at 4°C. 
Appropriate fluorochrome-conjugated secondary antibodies (Invitrogen) 
were used and sections were mounted using mounting media containing 
4,6-diamidino-2-phenylindole (Vector Laboratories). Imaging was performed 
using a microscope (Eclipse E800; Nikon) equipped with Plan Fluor objec-
tives (10×, NA 0.30; 20×, NA 0.50; 40×, NA 0.75) at room temperature in 
air using Alexa Fluor 594– and Alexa Fluor 488–coupled secondary antibodies. 
Images were acquired using a SPOT RTKE camera using the SPOT ad-
vanced software. For ultrastructural analysis, PNETs were fixed in 2% para-
formaldehyde and 2.5% glutaraldehyde followed by ferrocyanide-reduced 
osmium tetroxide. After uranyl staining en bloc, specimens were dehydrated 
and embedded in epoxy resin according to standard routines. Ultrathin sections 
were examined in an electron microscope (LEO 912AB; Omega) equipped 
with a camera (SiS Veleta; Olympus) under iTEM software control.
Animal care and tumor establishment. All animal experiments were 
approved by the local committees for animal care (Stockholm, Sweden and 
Newcastle, UK). Angiogenic islets from RIP1-Tag2 mice were defined as 
overtly red islets <1 × 1 mm, as assessed under a stereological microscope. 
Eng-iKOe mice and control mice were generated as previously described 
(Mahmoud et al., 2010). To establish EO771 tumors, 5 × 105 cells were in-
jected orthopically into the fourth mammary fat pad of young Eng+/+ or 
Eng+/ females. Anesthetized 8–12-wk-old female mice were injected with 
2.5 × 106 LLC-RFP cells subdermally. Tumor volume was calculated as 
length × width2 × /6.
Quantification of vascular parameters. Perfused vessels were assessed 
after 4 min of circulation of 50 µl of 0.5 mg/ml fluorescein-conjugated to-
mato lectin (Vector Laboratories) injected retroorbitally. Vessel density and 
perfusion was analyzed using Photoshop (Adobe), Volocity (PerkinElmer), 
or ImageJ (National Institutes of Health) software and quantified as number 
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